Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]

Completed · Phase 2 · Has a placebo group

Conditions studied: Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes

In brief

The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous coronary intervention (PCI). A select number of sites will also participate in a substudy where eligible patients will undergo an additional procedure;cardiac magnetic resonance imaging.

Key facts

Study ID

NCT00785954

Run by

KAI Pharmaceuticals

People needed

1180

Starts

2008-11-01

Expected to finish

2011-05-01

Last updated by the study team

2011-09-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Acute STEMI and has a planned emergent primary PCI procedure
• Continuous symptoms of cardiac ischemia and present to the primary PCI facility within 6 hours of symptom onset

You may not qualify if…

• Persistent systolic blood pressure < 90 mm Hg

Where it is running

• Study site — Escondido, California, United States
• Study site — Torrance, California, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Downers Grove, Illinois, United States
• Study site — Lombard, Illinois, United States
• Study site — Peoria, Illinois, United States
• Study site — Valparaiso, Indiana, United States
• Study site — Omaha, Nebraska, United States
• Study site — Williamsville, New York, United States
• Study site — Greensboro, North Carolina, United States
• Study site — High Point, North Carolina, United States
• Study site — Zanesville, Ohio, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Beaver, Pennsylvania, United States
• Study site — Danville, Pennsylvania, United States
• Study site — Bedford Park, Australia
• Study site — Boxhill, Australia
• Study site — Epping, Australia
• Study site — Fremantle, Australia
• Study site — Hobart, Australia
• Study site — Kogarah, Australia
• Study site — Liverpool, Australia
• Study site — Parkville, Australia
• Study site — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.